Piper Sandler raised the firm’s price target on Quest Diagnostics to $150 from $145 and keeps a Neutral rating on the shares. The firm is updating its estimates for Quest Diagnostics following the company’s earnings.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Becton Dickinson, Quest Diagnostics enter collaboration agreement
- Quest Diagnostics price target raised to $154 from $153 at Baird
- Quest Diagnostics raises FY24 adjusted EPS view to $8.80-$9.00 from $8.72-$8.97
- Quest Diagnostics reports Q2 adjusted EPS $2.35, consensus $2.34
- Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024